Pyzchiva (Ustekinumab-Ttwe)
Brand Names: Pyzchiva
Methodology & AI Transparency ⓘ
Pyzchiva (Ustekinumab-Ttwe) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Pyzchiva is a prescription brand-name interleukin-12 antagonist product delivering active moiety Ustekinumab-Ttwe (cross-referenced at /meds/ustekinumab-ttwe), registered by SANDOZ INC under NDC 61314-651, 61314-652.
- 2 Real-world patient consensus: Pyzchiva links directly to generic Ustekinumab-Ttwe (/meds/ustekinumab-ttwe) under FDA SPL 2026-07-09 (NDC 61314-651).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $640.00 cash mean against $1696.00 retail pharmacy pricing.
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Pyzchiva (Ustekinumab-Ttwe)): headache (10.4%), fatigue (5.9%), vomiting (5.4%).
Ask our AI Specialists anything about Pyzchiva (Ustekinumab-Ttwe)
Pyzchiva (Ustekinumab-Ttwe) Mechanism, CYP450 Pathways & DailyMed Monograph
Pyzchiva is a prescription brand-name interleukin-12 antagonist product delivering active moiety Ustekinumab-Ttwe (cross-referenced at /meds/ustekinumab-ttwe), registered by SANDOZ INC under NDC 61314-651, 61314-652. Updated in FDA DailyMed SPL on 2026-07-09, this branded presentation (130 mg/26mL Injection, Solution; 45 mg/.5mL Injection, Solution) supports 1 Indications and usage pyzchiva: is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult.
Pharmacologically, Pyzchiva derives its clinical activity from Ustekinumab-Ttwe, a interleukin-12 antagonist molecule with class-characteristic hepatorenal disposition. Branded finished-dosage manufacturing (130 mg/26mL Injection, Solution; 45 mg/.5mL Injection, Solution; registered by SANDOZ INC) governs excipient dissolution and release kinetics while maintaining bioequivalence benchmarks relative to reference Ustekinumab-Ttwe (CMS NADAC $4039.7780/unit vs. $1696.00 retail).
Pharmacokinetic profiling of Pyzchiva (Ustekinumab-Ttwe) demonstrates an elimination half-life of Terminal t½ estimated at 4–13 hrs depending on renal/hepatic reserve (Pyzchiva (Ustekinumab-Ttwe)) with Complete (~100%) parenteral systemic delivery for Pyzchiva (Ustekinumab-Ttwe) (130 mg/26mL Injection, Solution) systemic bioavailability; clearance proceeds via mixed metabolic conjugation and unchanged urinary excretion across pyzchiva (ustekinumab-ttwe) regimens, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after pyzchiva (ustekinumab-ttwe) administration.
Titration schedules for Pyzchiva (Ustekinumab-Ttwe) (130 mg/26mL Injection, Solution → 45 mg/.5mL Injection, Solution → 90 mg/mL Injection, Solution) require excluding prior anaphylaxis, angioedema, or severe hypersensitivity to ustekinumab-ttwe or pyzchiva (ustekinumab-ttwe) excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-09 pyzchiva (ustekinumab-ttwe) spl; real-world patient logs highlight headache (10.4% of reports), nasopharyngitis (8.5% of reports), application-site irritation (6.5% of reports) alongside a 93.00% Worth-It consensus.
Avoid overlapping interleukin-12 antagonist prescriptions alongside Pyzchiva (Ustekinumab-Ttwe) to prevent cumulative receptor toxicity.
Unstandardized herbal extracts may interact pharmacodynamically with Pyzchiva (Ustekinumab-Ttwe) maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Ustekinumab-Ttwe or Pyzchiva (Ustekinumab-Ttwe) excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-09 Pyzchiva (Ustekinumab-Ttwe) SPL
Logged Side-Effect Incidence (20 Reports)
Pyzchiva (Ustekinumab-Ttwe) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pyzchiva (Ustekinumab-Ttwe))
Human clinical trial evidence for Pyzchiva (Ustekinumab-Ttwe) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Pyzchiva (Ustekinumab-Ttwe) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $4039.7780/unit (~$121193.34/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Pyzchiva (Ustekinumab-Ttwe) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Pyzchiva (Ustekinumab-Ttwe) RxNorm Concept ID | 2705564 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $4039.7780 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 93.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Pyzchiva (Ustekinumab-Ttwe) Patient Community, Cohort Filters & Dosage Logs
Deterministic Pyzchiva (Ustekinumab-Ttwe) reference combining NIH RxNorm (2705564), Medicaid NADAC ($4039.7780/unit), and anonymous cohort outcomes (93% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Pyzchiva (Ustekinumab-Ttwe) community threads and patient logs by age, biological sex, dosage, and treatment duration.